What is Wedbush’s Estimate for TVTX FY2028 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at Wedbush dropped their FY2028 earnings per share estimates for shares of Travere Therapeutics in a report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $3.79 for the year, down from their previous estimate of $3.91. Wedbush has a “Outperform” rating and a $25.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

A number of other analysts have also recently weighed in on the company. Cantor Fitzgerald started coverage on Travere Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating for the company. Barclays raised their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Scotiabank raised their target price on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. Citigroup reduced their target price on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, September 27th. Finally, Leerink Partners restated an “outperform” rating and issued a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $24.00.

Travere Therapeutics Stock Down 2.4 %

Travere Therapeutics stock opened at $20.31 on Friday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -4.46 and a beta of 0.70. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $21.56. The business has a fifty day moving average price of $18.33 and a 200-day moving average price of $14.87.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business’s quarterly revenue was up 69.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.17) EPS.

Insider Buying and Selling at Travere Therapeutics

In related news, Director Roy D. Baynes sold 16,000 shares of Travere Therapeutics stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $20.00, for a total value of $320,000.00. Following the completion of the transaction, the director now owns 31,000 shares in the company, valued at $620,000. The trade was a 34.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP William E. Rote sold 2,437 shares of Travere Therapeutics stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the transaction, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,143 shares of company stock worth $1,167,512. Insiders own 3.75% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. abrdn plc purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at about $6,829,000. Jennison Associates LLC purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at about $14,222,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Travere Therapeutics by 23.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,206 shares of the company’s stock valued at $317,000 after purchasing an additional 3,494 shares in the last quarter. Baader Bank Aktiengesellschaft purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at about $192,000. Finally, R Squared Ltd acquired a new stake in Travere Therapeutics in the 4th quarter worth about $53,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.